An Open-Label, Randomized, Multi-Site Study to Assess the Pharmacokinetics of Single Subcutaneous Injections of 16mg and 64mg of GSK716155 Administered at Three Different Injection Sites in Adult Male and Female Subjects With Type 2 Diabetes and of Single Subcutaneous Injections of 16mg and 64mg of GSK716155 Administered in the Abdomen of Healthy, Normal Volunteers
Phase of Trial: Phase I
Latest Information Update: 14 Sep 2017
At a glance
- Drugs Albiglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 20 Apr 2008 Status changed from in progress to completed.
- 13 Feb 2007 Status changed from recruiting
- 12 Nov 2006 New trial record.